Glomerulonephritis
MONDO:0002462A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.
Also known as: glomerular nephritis, glomerulonephritis, glomerulonephritis (disease), nephritis of renal glomerulus, renal glomerulus nephritis, bright's disease
457 clinical trials for this condition and its sub-types, 33 tagged with Glomerulonephritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Glomerulonephritis
-
Lupus nephritis 140 trials
-
IgA glomerulonephritis 123 trials
-
Granulomatosis with polyangiitis 95 trials · 115 incl. sub-types
1 sub-type
-
Membranous glomerulonephritis 69 trials · 77 incl. sub-types
1 sub-type
- Idiopathic membranous glomerulonephritis 50 trials
-
Lipoid nephrosis 32 trials
-
Primary membranoproliferative glomerulonephritis 0 trials · 26 incl. sub-types
3 sub-types
- Complement 3 glomerulopathy 23 trials · 24 incl. sub-types Sub-types →
- Immunoglobulin-mediated membranoproliferative glomerulonephritis 12 trials
- Membranoproliferative glomerulonephritis, X-linked 0 trials
-
Membranoproliferative glomerulonephritis 11 trials
-
Pauci-immune glomerulonephritis 1 trial · 5 incl. sub-types
2 sub-types
-
Rapidly progressive glomerulonephritis 3 trials · 4 incl. sub-types
1 sub-type
-
Proliferative glomerulonephritis 1 trial · 2 incl. sub-types
1 sub-type
- Acute proliferative glomerulonephritis 0 trials · 1 incl. sub-types Sub-types →
-
Immunotactoid glomerulopathy 1 trial
-
Autoimmune glomerulonephritis 0 trials
-
Diffuse glomerulonephritis 0 trials
1 sub-type
- Acute diffuse glomerulonephritis 0 trials
-
Exudative glomerulonephritis 0 trials
-
Focal embolic glomerulonephritis 0 trials
-
Immune-complex glomerulonephritis 0 trials
-
Subacute glomerulonephritis 0 trials
Most studied deeper sub-types
-
New hope for kidney disease: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety of a drug called iptacopan for adults with a kidney disease called primary IgA nephropathy. Participants have already completed earlier studies and will continue taking the drug to monitor side effects and see if it helps slow kidney damag…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug aims to slow kidney failure in common kidney disease
Disease control OngoingThis phase 3 trial tests whether the drug atrasentan can slow kidney function loss in people with IgA nephropathy, a disease that can lead to kidney failure. About 404 participants receive either atrasentan or a placebo, along with standard care. The main goal is to see if atrase…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control OngoingThis phase 3 trial tests whether the drug povetacicept can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a kidney disease. About 605 participants will receive either the drug or a placebo by injection. The study is active but not recruit…
Phase 3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New shot shows promise in slowing kidney disease
Disease control OngoingThis phase 3 study tests BION-1301 (Zigakibart) in 383 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants receive either the drug or a placebo as a shot every 2 weeks for 2 years. The main goal is to see if the drug helps preserve kidney f…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
AI may spot hidden kidney transplant rejection
Knowledge-focused OngoingThis study is developing an artificial intelligence (AI) system to analyze kidney biopsy images from transplant patients. The goal is to see if AI can accurately tell apart different types of rejection, measure how much damage the kidney has, and predict if rejection might come b…
Sponsor: Chen Dajin • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC